The UK's most complete GLP-1 guide
Every Question Answered. Every Side Effect Explained.
- How GLP-1 medications work
- Mounjaro vs Wegovy compared
- Injection instructions
- Side effects & solutions
- What to eat on treatment
- FAQs answered
Free tracker included with every download this week
Understanding Tirzepatide Long-Term Side Effects in the UK
Tirzepatide, the active ingredient in Mounjaro, is a dual GIP and GLP-1 receptor agonist now prescribed through NHS specialist services and private clinics across the UK. While short-term side effects like nausea are well documented, many people want to know what happens with long-term use. This guide explains what current evidence shows about tirzepatide's safety profile over extended treatment periods, based on NHS guidance and clinical trial data.
10,000+ calculations today · NHS-aligned thresholds · 100% free
Calculate Your BMI Instantly
Enter your height and weight below. Supports both imperial (stone & lbs) and metric (kg). Results include NHS category, healthy weight range, and ethnicity adjustments.
What Is BMI and Why Does It Matter?
Body Mass Index (BMI) is the most widely used screening tool for assessing whether your weight falls within a healthy range. Used by the NHS, GPs, and weight management services across the UK, BMI provides a quick snapshot of your weight relative to your height. The formula is simple: your weight in kilograms divided by your height in metres squared (kg/m²).
While BMI isn't a perfect measure — it doesn't account for muscle mass, bone density, or fat distribution — it remains the standard first step in identifying potential weight-related health risks including type 2 diabetes, cardiovascular disease, high blood pressure, and certain cancers.
The NHS also recommends adjusted thresholds for people of South Asian, Chinese, or Black African heritage — a BMI of 23 or above is classified as overweight, and 27.5 as obese. Our calculator includes this adjustment as a one-click toggle.
What the Research Shows About Long-Term Tirzepatide Safety
The SURMOUNT clinical trials, which informed UK approval of tirzepatide for weight management, tracked participants for up to 72 weeks — providing the longest safety data currently available. Most side effects occurring during long-term use are the same as those experienced early on, including nausea, diarrhoea, constipation, and vomiting, though severity often decreases over time as the body adjusts to the weekly weight loss injection.
- Gastrointestinal effects: Nausea typically peaks in the first 4–8 weeks, then improves. Diarrhoea and constipation often resolve with dose stabilisation.
- Hair loss: Alopecia (hair shedding) has been reported in longer-term use, likely related to gradual weight management rather than the drug itself — similar to outcomes seen with other weight loss methods.
- Muscle loss: GLP-1 receptor agonists may contribute to lean muscle loss alongside fat loss. The NHS recommends combining treatment with strength training and adequate protein intake.
- Fatigue and dizziness: These typically improve within the first 12 weeks but can persist in some users at higher doses.
The MHRA (UK medicines regulator) continues to monitor tirzepatide safety through ongoing surveillance, and no major new long-term safety concerns have emerged beyond those identified in clinical trials.
Clinically BackedWeight Loss
No appointments. No waiting rooms. Just care — from a UK-regulated online pharmacy.
How It Works
Three simple steps to understand your weight and take action.
Enter your height and weight in our free calculator. Get your BMI, NHS category, healthy weight range, and ethnicity-adjusted thresholds instantly.
If your BMI suggests you're overweight or obese, explore our GLP-1 calculators to project potential weight loss on Mounjaro or Wegovy.
Use our progress tracker to log your weight weekly, visualise your journey with charts, and stay motivated — all stored privately in your browser.
Free Weight Loss Tools & Guides
Everything you need to understand your weight, explore medication options, and track your progress — completely free.
NHS Prescribing Guidance and Long-Term Management
In the UK, tirzepatide prescriptions through NHS tier 3 weight management services include structured follow-up appointments to monitor for emerging side effects and assess continued benefit. Treatment is not intended to be indefinite — the NHS approach involves reviewing whether to continue, pause, or stop tirzepatide after 12–24 months based on individual response and any developing concerns. Your GP or specialist will discuss the balance of benefits versus risks with you throughout treatment. If you develop new symptoms or experience worsening side effects, contact your healthcare provider immediately rather than adjusting your dose independently. Using our GLP-1 weight loss calculator can help you understand realistic expectations alongside structured NHS care.
- Dual GIP/GLP-1 receptor agonist
- Up to 22.5% body weight loss (SURMOUNT-1)
- Weekly injection, dose escalation over 20+ weeks
- Available via private prescription in the UK
- Doses: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg
- GLP-1 receptor agonist
- Up to 15–17% body weight loss (STEP trials)
- Weekly injection, 5-step dose escalation
- NHS & private prescription available
- Doses: 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg
Mounjaro vs Wegovy: Head-to-Head
A side-by-side comparison of the two most popular GLP-1 weight loss medications available in the UK.
| Feature | Mounjaro | Wegovy |
|---|---|---|
| Drug class | Dual GIP/GLP-1 agonist | GLP-1 agonist |
| Active ingredient | Tirzepatide | Semaglutide |
| Avg. weight loss | 15–22.5% | 12–17% |
| Key trial | SURMOUNT-1 (2022) | STEP 1 (2021) |
| Max dose | 15 mg weekly | 2.4 mg weekly |
| Escalation period | 20–32 weeks | 16–20 weeks |
| Administration | Weekly injection (pen) | Weekly injection (pen) |
| NHS availability | Private prescription only | NHS & private |
| Approx. private cost | £150–£250/month | £150–£300/month |
| Common side effects | Nausea, diarrhoea, constipation | Nausea, vomiting, diarrhoea |
Data sourced from SURMOUNT-1 and STEP 1 clinical trials. Costs are approximate and vary by provider. Always consult a prescriber.
Am I Eligible for Weight Loss Medication?
In the UK, eligibility for GLP-1 weight loss medications like Mounjaro and Wegovy is based on your BMI and overall health profile.
- BMI of 30 or above (obese)
- Age 18 or over
- No contraindicated conditions
- Committed to lifestyle changes
- BMI of 27 or above
- Plus type 2 diabetes
- Or high blood pressure
- Or obstructive sleep apnoea
Use our BMI calculator to check whether your BMI falls within the eligible range.
How We Built These Tools
Every calculator and guide on myweightcheck is built with accuracy and transparency in mind. Our BMI calculator uses the standard WHO formula with NHS-aligned category thresholds. Our GLP-1 projections are modelled on published clinical trial data from SURMOUNT and STEP studies.
All data stays on your device. We don't require sign-ups, and we don't store your health information on any server. Your progress tracker saves data locally in your browser using localStorage, so only you can see it.
We're based in the UK and our tools are designed specifically for UK users — supporting stone & lbs by default, referencing NHS guidelines, using NICE-approved medication data, and linking to GPhC-registered pharmacies.
Frequently Asked Questions
Common questions about BMI, weight loss medications, and our free UK tools.
Can tirzepatide cause permanent side effects?
No permanent side effects have been documented in clinical trials lasting up to 72 weeks. Most side effects either resolve with continued use or improve when the dose is stabilised. Hair loss related to gradual weight management typically reverses after weight loss plateaus. Always report any new or concerning symptoms to your prescriber.
Does nausea get worse with long-term tirzepatide use?
The opposite — nausea typically improves with time. It usually peaks at weeks 4–8 after starting or increasing the dose, then gradually lessens as your body adapts. By 12 weeks, most people report significant improvement. Eating smaller meals and avoiding fatty foods can help manage nausea in the meantime.
Is tirzepatide safe to use for years?
Safety data beyond 72 weeks is limited, as tirzepatide is relatively new. The NHS and MHRA monitor long-term outcomes continuously. Treatment is typically reviewed at 12–24 months to assess whether continuing is appropriate. Your prescriber will help you decide based on your individual health profile and response.
What should I do if I develop a new side effect after months of using tirzepatide?
Contact your GP or specialist immediately — do not assume it will resolve on its own. Some side effects, like severe abdominal pain, changes in vision, or persistent fatigue, require urgent assessment. Your healthcare provider can adjust your treatment plan or investigate other causes.
Does the weekly weight loss injection lose effectiveness over time?
Some people experience a weight loss plateau after 6–12 months as the body adapts. This is normal and not a "loss of effectiveness." Your prescriber may explore whether increasing the dose (if not already at maximum) or combining treatment with dietary and exercise changes helps. Tracking your progress with our free progress tracker can help identify patterns.
Ready to take control of your weight loss journey?
Start with a free BMI check, explore your GLP-1 options, or begin tracking your progress today. No sign-up. No cost. Just results.